William Blair & Company
DNTH icon

William Blair & Company’s Dianthus Therapeutics DNTH Stock Holding History

William Blair & Company’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.93M Buy
19,779
+1,498
+8% +$131K 0.01% 768
2026
Q1 		$1.53M Buy
18,281
+356
+2% +$20.6K ﹤0.01% 814
2025
Q4 		$739K Buy
17,925
+2,050
+13% +$79.5K ﹤0.01% 1018
2025
Q3 		$625K Buy
+15,875
New +$406K ﹤0.01% 1044

Other funds holding DNTH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

William Blair & Company's DNTH Position: Q2 2026 in Review

William Blair & Company increased its Dianthus Therapeutics (DNTH) stake by 8.2% in Q2 2026, buying an estimated $131K and bringing the position to 19,779 shares worth $1.93M. The position accounts for 0.01% of the portfolio, ranked #768.

William Blair & Company first reported a position in DNTH in Q3 2025 and has held it in 4 quarters since. 270 funds tracked by Wall St. Rank hold DNTH as of Q2 2026.

  • William Blair & Company held 19,779 shares of Dianthus Therapeutics worth $1.93M as of Q2 2026.
  • William Blair & Company bought 1,498 Dianthus Therapeutics shares in Q2 2026, an estimated $131K.
  • Dianthus Therapeutics made up 0.01% of William Blair & Company's portfolio in Q2 2026, its #768 holding.
  • William Blair & Company first reported a position in Dianthus Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • 270 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q2 2026.

Based on William Blair & Company's 13F filing for Q2 2026, filed 11 Aug 2026.